BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 12405274)

  • 1. The glitazones: a new treatment for type 2 diabetes mellitus.
    Bradley C
    Intensive Crit Care Nurs; 2002 Jun; 18(3):189-91. PubMed ID: 12405274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation.
    Czoski-Murray C; Warren E; Chilcott J; Beverley C; Psyllaki MA; Cowan J
    Health Technol Assess; 2004 Apr; 8(13):iii, ix-x, 1-91. PubMed ID: 15038907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pioglitazone and rosiglitazone for diabetes.
    Drug Ther Bull; 2001 Sep; 39(9):65-8. PubMed ID: 11586802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence.
    Diamant M; Heine RJ
    Drugs; 2003; 63(13):1373-405. PubMed ID: 12825962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.
    Mudaliar S; Henry RR
    Annu Rev Med; 2001; 52():239-57. PubMed ID: 11160777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Insulin sensitizer. A new therapy option for type 2 diabetic patients].
    Filz HP
    MMW Fortschr Med; 2000 Sep; 142(38):31-3. PubMed ID: 11050888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The glitazones: proceed with caution.
    Krische D
    West J Med; 2000 Jul; 173(1):54-7. PubMed ID: 10903299
    [No Abstract]   [Full Text] [Related]  

  • 8. Insulin resistance and its treatment by thiazolidinediones.
    Lebovitz HE; Banerji MA
    Recent Prog Horm Res; 2001; 56():265-94. PubMed ID: 11237217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatotoxicity with thiazolidinediones: is it a class effect?
    Scheen AJ
    Drug Saf; 2001; 24(12):873-88. PubMed ID: 11735645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving management of type 2 diabetes mellitus: 5. Thiazolidinediones.
    Samraj GP; Kuritzky L; Quillen DM
    Hosp Pract (1995); 2000 Jan; 35(1):123-4, 129-32. PubMed ID: 10645993
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus.
    Füchtenbusch M; Standl E; Schatz H
    Exp Clin Endocrinol Diabetes; 2000; 108(3):151-63. PubMed ID: 10926309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glitazones: clinical effects and molecular mechanisms.
    Stumvoll M; Häring HU
    Ann Med; 2002; 34(3):217-24. PubMed ID: 12173692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thiazolidinediones in the treatment of type 2 diabetes.
    Pittas AG; Greenberg AS
    Expert Opin Pharmacother; 2002 May; 3(5):529-40. PubMed ID: 11996632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pioglitazone insulin sensitivity and type 2 diabetes mellitus: recent data].
    Monnier L; Sauvanet JP
    Ann Endocrinol (Paris); 2004 Apr; 65(2):136-48. PubMed ID: 15247874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiating members of the thiazolidinedione class: a focus on efficacy.
    Goldstein BJ
    Diabetes Metab Res Rev; 2002; 18 Suppl 2():S16-22. PubMed ID: 11921434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials.
    Krentz AJ; Bailey CJ; Melander A
    BMJ; 2000 Jul; 321(7256):252-3. PubMed ID: 10915108
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records.
    Boyle PJ; King AB; Olansky L; Marchetti A; Lau H; Magar R; Martin J
    Clin Ther; 2002 Mar; 24(3):378-96. PubMed ID: 11952022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type 2 diabetes, thiazolidinediones, and cardiovascular risk.
    Taylor C; Hobbs FD
    Br J Gen Pract; 2009 Jul; 59(564):520-4. PubMed ID: 19567003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glitazones and the potential improvement of lipid profiles in diabetes patients at high risk for cardiovascular disease.
    Nass CM; Blumenthal RS
    Am J Manag Care; 2000 Dec; 6(24 Suppl):S1247-56; quiz S1257-8. PubMed ID: 11142005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are all glitazones the same?
    Van Gaal L; Scheen AJ
    Diabetes Metab Res Rev; 2002; 18 Suppl 2():S1-4. PubMed ID: 11921431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.